Find A Physician
More on Heart Transplant
Research and Clinical Trials
More on Heart Transplant
The Heart Failure and Transplantation Program at NewYork-Presbyterian Hospital is the largest and most active heart transplant program in the nation.
The program consistently treats patients with serious conditions and high risks, including those with:
- cardiac amyloidosis
- diabetes-related end-stage organ damage
- and HIV.
While caring for these high-risk patients, the Program's survival rates have consistently met or exceeded the national average since its inception in 1977.
Our Heart Transplant Centers
Patients with end-stage cardiac disease can receive care at both NewYork-Presbyterian's Weill Cornell Medical Center and Columbia University Medical Center campuses. Both locations offer specialized programs in heart failure: The Center for Advanced Cardiac Care at NewYork-Presbyterian/Columbia and The Perkin Center for Heart Failure at the Ronald O. Perelman Heart Institute of NewYork-Presbyterian Hospital/Weill Cornell.
Expanding Care to More Patients
The heart transplant program has implemented extended criteria protocols for both organ donors and transplant recipients, changes that are significantly widening the availability of organs and providing the option of transplantation to patients who would otherwise be denied treatment. Under these new protocols surgeons now routinely transplant donor hearts that don't meet the usual criteria for transplantation, but are nevertheless healthy enough for a successful transplant. These donor hearts may be offered to patients over age 65 or those formerly considered too compromised to undergo transplantation.
Physician-researchers in the Heart Failure and Transplantation Program are making continuous advances in medical therapies, surgical techniques, immunologic therapies, imaging methods, and device development. The Program's innovations include:
- the first mechanical bridge-to-transplantation using intra-aortic balloon pumps, in the 1970s;
- the first pediatric heart transplant, in 1984;
- the development of minimally invasive and hybrid (surgical-catheter based) cardiac procedures;
- the development of third-generation LVAD technologies;
- the improvement of immunosuppressant regimens;
- the creation of a gene-based blood test to replace heart biopsies to detect rejection after transplantation;
- the implementation of extended criteria organ transplantation to improve access to transplantation; and
- the use of gene therapy in the treatment of heart failure.
Heart and Lung Transplants
Surgeons from the Heart Failure and Transplantation Program and the Center for Lung Disease and Transplantation at NewYork-Presbyterian collaborate to perform combination heart and lung transplants for patients who need both organs transplanted.
Heart Failure and Transplantation Program